FinscoFinsco

Arrowhead Pharmaceuticals (US.ARWR)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ARWR · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion95.2%→
ROE-16.6%↓
Cash Conversion-→
D/E Ratio1.61↓
Gross Margin0.0%↓
US.ARWR (Arrowhead Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    95.2%    →
ROE              -16.6%    ↓
Cash Conversion       -    →
D/E Ratio          1.61    ↓
Gross Margin       0.0%    ↓
Key Metrics
US.ARWR (Arrowhead Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 95.2% →
ROE -16.6% ↓
Cash Conversion - →
D/E Ratio 1.61 ↓
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies